Milliken-Zickert Syndrome

Millikan-Sieker syndrome is a rare hereditary disease characterized by impaired muscle development and function. The syndrome was first described in 1948 by American physician Charles Milliken and his colleague Robert Sickert.

Millikan-Sikkert syndrome manifests itself in the form of various disorders of muscle function. Patients may experience weakness, paralysis, muscle atrophy, poor coordination and other symptoms. The cause of the syndrome is a genetic mutation that disrupts the normal development and functioning of muscle cells.

Treatment for Millikan-Sikkert syndrome includes medication, physical therapy, massage, and exercise therapy. However, in most cases, treatment does not bring significant results and the symptoms of the disease persist throughout the patient’s life.

The prognosis for Millikan-Sikkert syndrome depends on the severity of symptoms and the degree of impairment of muscle function. In some cases, the disease can lead to disability and severe limitations in daily life. However, with timely initiation of treatment and the right approach to rehabilitation, patients can maintain some degree of motor activity and social adaptation.

**Millikan-Sickert syndrome:**

Congoerythrokeratoglobus is a change in the color of the sclera (erythrosculosis) and pupil (myophiascoma) described by the American ophthalmologist Millen Milliken in 1958. Signs of cataracts. Insufficient development of the ciliary body or its clouding leads to atrophy or improper development of the ciliary muscle. At the same time, it does not put pressure on the lens and it remains “inverted.” The ciliary reflex is not developed. As a result, amaurosis and myopia are formed. The syndrome is characterized by decreased sensitivity of the cornea (monocyte-monogenic syndrome)